NO329827B1 - Anvendelse av inhibitorer av IL-18 produksjon og/eller dets virkning ved fremstilling av medikamenter for a hemme metastase av melanom, og anvendelse av en ekspresjonsvektor som koder for en inhibitor for IL-18 produksjon og deller dets virkning ved fremstillingen av medikamenter for a hemme metastase av melanom - Google Patents
Anvendelse av inhibitorer av IL-18 produksjon og/eller dets virkning ved fremstilling av medikamenter for a hemme metastase av melanom, og anvendelse av en ekspresjonsvektor som koder for en inhibitor for IL-18 produksjon og deller dets virkning ved fremstillingen av medikamenter for a hemme metastase av melanom Download PDFInfo
- Publication number
- NO329827B1 NO329827B1 NO20020153A NO20020153A NO329827B1 NO 329827 B1 NO329827 B1 NO 329827B1 NO 20020153 A NO20020153 A NO 20020153A NO 20020153 A NO20020153 A NO 20020153A NO 329827 B1 NO329827 B1 NO 329827B1
- Authority
- NO
- Norway
- Prior art keywords
- cells
- production
- hse
- metastasis
- inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims description 36
- 206010027476 Metastases Diseases 0.000 title claims description 32
- 230000009401 metastasis Effects 0.000 title claims description 26
- 230000000694 effects Effects 0.000 title claims description 25
- 230000031037 interleukin-18 production Effects 0.000 title claims description 20
- 201000001441 melanoma Diseases 0.000 title claims description 11
- 239000003814 drug Substances 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title claims description 7
- 239000013604 expression vector Substances 0.000 title claims description 4
- 108090000171 Interleukin-18 Proteins 0.000 claims description 80
- 102000003810 Interleukin-18 Human genes 0.000 claims description 78
- 102000044166 interleukin-18 binding protein Human genes 0.000 claims description 26
- 108010070145 interleukin-18 binding protein Proteins 0.000 claims description 26
- 102000004557 Interleukin-18 Receptors Human genes 0.000 claims description 17
- 108010017537 Interleukin-18 Receptors Proteins 0.000 claims description 17
- 230000009471 action Effects 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 6
- 230000019491 signal transduction Effects 0.000 claims description 5
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 claims description 2
- 102100035017 Interleukin-18-binding protein Human genes 0.000 claims 2
- 101710205006 Interleukin-18-binding protein Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 135
- 208000001382 Experimental Melanoma Diseases 0.000 description 51
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 27
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 27
- 102000004127 Cytokines Human genes 0.000 description 22
- 108090000695 Cytokines Proteins 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 241001529936 Murinae Species 0.000 description 12
- 102000000589 Interleukin-1 Human genes 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 108010002352 Interleukin-1 Proteins 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000000770 proinflammatory effect Effects 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 9
- 230000003827 upregulation Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 108020003519 protein disulfide isomerase Proteins 0.000 description 6
- 230000006433 tumor necrosis factor production Effects 0.000 description 6
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000003305 autocrine Effects 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 102100035904 Caspase-1 Human genes 0.000 description 4
- 108090000426 Caspase-1 Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000011870 unpaired t-test Methods 0.000 description 3
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 108010031099 Mannose Receptor Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000019189 interleukin-1 beta production Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000000684 melanotic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001480 pro-metastatic effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- -1 6-carboxyfluorescein acetoxymethyl ester Chemical class 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101000828805 Cowpox virus (strain Brighton Red) Serine proteinase inhibitor 2 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101001057956 Homo sapiens 55 kDa erythrocyte membrane protein Proteins 0.000 description 1
- 101000837415 Homo sapiens DNA polymerase subunit gamma-2, mitochondrial Proteins 0.000 description 1
- 101001065272 Homo sapiens EGF-containing fibulin-like extracellular matrix protein 1 Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 description 1
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 1
- 101710149731 Interleukin-1 receptor type 2 Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- NTECHUXHORNEGZ-UHFFFAOYSA-N acetyloxymethyl 3',6'-bis(acetyloxymethoxy)-2',7'-bis[3-(acetyloxymethoxy)-3-oxopropyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound O1C(=O)C2=CC(C(=O)OCOC(C)=O)=CC=C2C21C1=CC(CCC(=O)OCOC(C)=O)=C(OCOC(C)=O)C=C1OC1=C2C=C(CCC(=O)OCOC(=O)C)C(OCOC(C)=O)=C1 NTECHUXHORNEGZ-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 108010027836 endotoxin receptor Proteins 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 102000057036 human EFEMP1 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL13104799A IL131047A0 (en) | 1999-07-22 | 1999-07-22 | Use of il-18 inhibitors |
| PCT/IL2000/000419 WO2001007480A2 (en) | 1999-07-22 | 2000-07-17 | Use of interleukin-18 inhibitors to inhibit tumor metastasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20020153D0 NO20020153D0 (no) | 2002-01-11 |
| NO20020153L NO20020153L (no) | 2002-03-11 |
| NO329827B1 true NO329827B1 (no) | 2011-01-03 |
Family
ID=11073044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20020153A NO329827B1 (no) | 1999-07-22 | 2002-01-11 | Anvendelse av inhibitorer av IL-18 produksjon og/eller dets virkning ved fremstilling av medikamenter for a hemme metastase av melanom, og anvendelse av en ekspresjonsvektor som koder for en inhibitor for IL-18 produksjon og deller dets virkning ved fremstillingen av medikamenter for a hemme metastase av melanom |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7741276B2 (ru) |
| EP (1) | EP1206274B1 (ru) |
| JP (1) | JP4827352B2 (ru) |
| KR (1) | KR100682219B1 (ru) |
| CN (1) | CN1173736C (ru) |
| AR (1) | AR024907A1 (ru) |
| AT (1) | ATE363288T1 (ru) |
| AU (1) | AU782478B2 (ru) |
| BG (1) | BG65800B1 (ru) |
| BR (1) | BR0012675A (ru) |
| CA (1) | CA2380216C (ru) |
| CY (1) | CY1107932T1 (ru) |
| CZ (1) | CZ302114B6 (ru) |
| DE (2) | DE1206274T1 (ru) |
| DK (1) | DK1206274T3 (ru) |
| EA (1) | EA005419B1 (ru) |
| EE (1) | EE04838B1 (ru) |
| ES (1) | ES2186596T3 (ru) |
| HK (1) | HK1048248B (ru) |
| HU (1) | HU228780B1 (ru) |
| IL (2) | IL131047A0 (ru) |
| MX (1) | MXPA02000838A (ru) |
| NO (1) | NO329827B1 (ru) |
| NZ (1) | NZ516535A (ru) |
| PL (1) | PL202477B1 (ru) |
| PT (1) | PT1206274E (ru) |
| SK (1) | SK287522B6 (ru) |
| TR (1) | TR200200169T2 (ru) |
| UA (1) | UA73745C2 (ru) |
| WO (1) | WO2001007480A2 (ru) |
| ZA (1) | ZA200200390B (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI373343B (en) | 2000-02-10 | 2012-10-01 | Abbott Gmbh & Co Kg | Antibodies that bind human interleukin-18 and methods of making and using |
| AU1174402A (en) | 2000-10-11 | 2002-04-22 | Viron Therapeutics Inc | Nucleic acid molecules and polypeptides for immune modulation |
| US7718368B2 (en) | 2000-12-04 | 2010-05-18 | Viron Therapeutics Inc. | Immunomodulatory protein and useful embodiments thereof |
| MXPA05003869A (es) * | 2002-10-08 | 2005-06-22 | Ares Trading Sa | El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina. |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| WO2006128908A1 (en) | 2005-06-03 | 2006-12-07 | Ares Trading S.A. | Production of recombinant il-18 binding protein |
| EP1891088B1 (en) | 2005-06-10 | 2011-10-19 | Ares Trading S.A. | Process for the purification of il-18 binding protein |
| CL2008002153A1 (es) | 2007-07-24 | 2009-06-05 | Amgen Inc | Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r. |
| US9812033B2 (en) * | 2013-03-06 | 2017-11-07 | Venkatesh R. Chari | Tactile graphic display |
| WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT69922A (en) * | 1992-09-02 | 1995-09-28 | Isis Pharmaceuticals Inc | Oligonucleotide modification of cell adhesion |
| US7141393B2 (en) * | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| BR9810409A (pt) * | 1997-03-18 | 2000-08-22 | Basf Ag | Métodos e composições para a modulação de responsividade a corticosteróides |
| IL121860A0 (en) * | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
-
1999
- 1999-07-22 IL IL13104799A patent/IL131047A0/xx unknown
-
2000
- 2000-07-17 ES ES00944201T patent/ES2186596T3/es not_active Expired - Lifetime
- 2000-07-17 UA UA2002021472A patent/UA73745C2/uk unknown
- 2000-07-17 TR TR2002/00169T patent/TR200200169T2/ unknown
- 2000-07-17 CA CA2380216A patent/CA2380216C/en not_active Expired - Lifetime
- 2000-07-17 CZ CZ20020195A patent/CZ302114B6/cs not_active IP Right Cessation
- 2000-07-17 WO PCT/IL2000/000419 patent/WO2001007480A2/en active IP Right Grant
- 2000-07-17 MX MXPA02000838A patent/MXPA02000838A/es active IP Right Grant
- 2000-07-17 SK SK88-2002A patent/SK287522B6/sk not_active IP Right Cessation
- 2000-07-17 PT PT00944201T patent/PT1206274E/pt unknown
- 2000-07-17 EP EP00944201A patent/EP1206274B1/en not_active Expired - Lifetime
- 2000-07-17 AU AU58432/00A patent/AU782478B2/en not_active Expired
- 2000-07-17 JP JP2001512563A patent/JP4827352B2/ja not_active Expired - Lifetime
- 2000-07-17 DK DK00944201T patent/DK1206274T3/da active
- 2000-07-17 CN CNB008106894A patent/CN1173736C/zh not_active Expired - Lifetime
- 2000-07-17 BR BR0012675-6A patent/BR0012675A/pt not_active IP Right Cessation
- 2000-07-17 EA EA200200189A patent/EA005419B1/ru not_active IP Right Cessation
- 2000-07-17 PL PL353732A patent/PL202477B1/pl unknown
- 2000-07-17 NZ NZ516535A patent/NZ516535A/en not_active IP Right Cessation
- 2000-07-17 KR KR1020027000682A patent/KR100682219B1/ko active IP Right Grant
- 2000-07-17 AT AT00944201T patent/ATE363288T1/de active
- 2000-07-17 EE EEP200200032A patent/EE04838B1/xx unknown
- 2000-07-17 HU HU0202107A patent/HU228780B1/hu unknown
- 2000-07-17 DE DE1206274T patent/DE1206274T1/de active Pending
- 2000-07-17 DE DE60035049T patent/DE60035049T2/de not_active Expired - Lifetime
- 2000-07-21 AR ARP000103786A patent/AR024907A1/es unknown
-
2002
- 2002-01-11 NO NO20020153A patent/NO329827B1/no not_active IP Right Cessation
- 2002-01-16 BG BG106311A patent/BG65800B1/bg unknown
- 2002-01-16 ZA ZA200200390A patent/ZA200200390B/xx unknown
- 2002-01-17 IL IL147675A patent/IL147675A/en unknown
- 2002-11-11 HK HK02108154.3A patent/HK1048248B/zh not_active IP Right Cessation
-
2007
- 2007-07-06 US US11/825,548 patent/US7741276B2/en not_active Expired - Fee Related
- 2007-07-13 CY CY20071100938T patent/CY1107932T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7741276B2 (en) | Use of interleukin-18 inhibitors to inhibit tumor metastasis | |
| Smith et al. | CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF | |
| JP2018087244A (ja) | 炎症性疾患および自己免疫疾患の処置の組成物および方法 | |
| Biswas et al. | Cross-linking of CD30 induces HIV expression in chronically infected T cells | |
| BG65242B1 (bg) | Свързващи протеини и рецептори на остеопротегерин | |
| JPH10511266A (ja) | ヒト・インターロイキン−１１受容体 | |
| CA2237915A1 (en) | Osteoporosis treatment | |
| US20030017151A1 (en) | Therapeutic use of rank antagonists | |
| Santo et al. | Selective inhibition of TNFR1 reduces osteoclast numbers and is differentiated from anti-TNF in a LPS-driven model of inflammatory bone loss | |
| Kanda et al. | Transforming growth factor α protects against Fas-mediated liver apoptosis in mice | |
| JPH0725785A (ja) | インターロイキン−６の医薬組成物 | |
| Berghen et al. | P101 DOT1L inhibition increases dermal fibroblast proliferation but has no effects on in vitro or in vivo collagen deposition in models of fibrosis | |
| KR101769122B1 (ko) | 케모카인 발현 조절제 | |
| JP2021523892A (ja) | Ｏｃａ−ｂペプチドコンジュゲート及び処置方法 | |
| Jiang | Increased core temperature during febrile disease modulates cytokine expression, enhances host defense, and improves survival in bacterial infection | |
| Medvedev et al. | A Non‐Competitive P55 TNF Receptor Antibody Enhances the Specific Activity of Lymphotoxin‐α | |
| EP1516627A1 (en) | Interferon-Gamma for the treatment of diseases associated with the NOD2 gene | |
| Piccoli et al. | Hyporesponsiveness of Natural Killer Activity Induced in Vivo By Multiple Treatment with Maleic Acid Anhydride Divinyl Ether (MVE-2) | |
| AU2002257303A1 (en) | Therapeutic use of rank antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |